Published in

Elsevier, Medical Hypotheses, 3(64), p. 505-511

DOI: 10.1016/j.mehy.2004.07.039

Links

Tools

Export citation

Search in Google Scholar

The use of transformed Escherichia coli for experimental angiogenesis induced by regulated in situ production of vascular endothelial growth factor – an alternative gene therapy

Journal article published in 2005 by Peter Celec, Roman Gardlík, Roland Pálffy, Július Hodosy, Stanislav Stuchlík, Hana Drahovská, Martina Stuchlíková, Gabriel Minárik, Ján Lukács, Ingrid Jurkovičová, Ivan Hulín, Ján Turňa, Ján Jakubovský, Martin Kopáni, Ľuboš Danišovič and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Red circle
Postprint: archiving forbidden
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Defects in angiogenesis (blood vessel formation) are responsible for two most important causes of death in developed countries (ischemic heart disease and cancer). Vascular endothelial growth factor (VEGF) plays a pivotal role in physiological and pathological regulation of angiogenesis. In the last years several studies have indicated the possibilities of VEGF in the therapy of ischemic heart disease. However, especially VEGF gene therapy (naked DNA, plasmids and adenovirus mediated) is associated with adverse side effects regarding the expression regulation.